Treatment of PTLD has been importantly strengthened by Rituximab, a humanized anti-CD20 antibody, which has been widely approved against CD20 positive malignant lymphoma including DLBCL [23]. The gene discussed is MS4A1; the disease is diffuse large B-cell lymphoma.